Bruker Corporation reported second-quarter 2026 revenue of $838.5 million, up 5.2% year-over-year, marking a return to organic growth of 2.8%, or 3.4% excluding U.S. tariff refunds. Non-GAAP earnings per share rose 53% to $0.49, driven by cost-saving actions and a net tariff refund benefit, while GAAP results included a diluted loss per share of $0.41 due to a noncash goodwill impairment charge of $135 million related to automation and spatial biology businesses. The company saw strong bookings, with Scientific Instruments organic orders up 10%, biopharma bookings growing more than 20%, and semiconductor metrology orders surging over 50% organically. Bruker maintained its full-year 2026 non-GAAP EPS guidance of $2.10 to $2.15, representing 15% to 17% growth, and expects fourth-quarter revenue of $1.02 billion to $1.04 billion with meaningful margin expansion.
Bruker CorporationQ2 revenue growth and raised EPS outlook driven by cost savings and tariff refunds, despite goodwill impairment.
